首页> 外文期刊>Cardiovascular Research >MicroRNAs: novel regulators in cardiac development and disease.
【24h】

MicroRNAs: novel regulators in cardiac development and disease.

机译:MicroRNA:心脏发育和疾病中的新型调节剂。

获取原文
获取原文并翻译 | 示例
           

摘要

MicroRNAs (miRNAs) are endogenous, small ribonucleotides regulating the translation of target messenger RNAs that have been shown to be involved in orchestrating growth, development, function, and stress responses of various organs, including the heart. Muscle miRNAs are mainly controlled by a network of myogenic transcription factors, and throughout cardiac development they fine-tune regulatory protein levels in a spatiotemporal manner. Recent profiling studies revealed that miRNA expression patterns are derailed in both human cardiac disease and animal models of cardiac hypertrophy and failure. Modulation of miRNA expression in vitro as well as in vivo has revealed an important role of miRNAs in regulating heart function, particularly cardiac growth and conductance. Here, we overview the recent findings on miRNAs in cardiac development and disease and report the latest advances in the identification and validation of miRNA targets, which are important for a comprehensive understanding of cardiac miRNA function. Finally, we focus on the development and use of miRNA antagonists (antagomirs) to target miRNAs in vivo, which may translate into novel therapeutic strategies for heart disease in the future.
机译:微小RNA(miRNA)是内源性的小核糖核苷酸,可调节目标信使RNA的翻译,已证明它们参与协调包括心脏在内的各种器官的生长,发育,功能和应激反应。肌肉miRNA主要受成肌转录因子网络控制,在整个心脏发育过程中,它们以时空方式微调调节蛋白的水平。最近的分析研究表明,miRNA表达模式在人类心脏疾病以及心脏肥大和衰竭的动物模型中均脱轨。在体内外对miRNA表达的调节揭示了miRNA在调节心脏功能(尤其是心脏生长和电导)中的重要作用。在这里,我们概述了有关心脏发育和疾病中miRNA的最新发现,并报告了miRNA靶标的鉴定和验证的最新进展,这对于全面了解心脏miRNA的功能非常重要。最后,我们专注于miRNA拮抗剂(antagomirs)的开发和使用,以在体内靶向miRNA,这可能会在将来转化为心脏病的新型治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号